Association between Food Intake and Gastrointestinal Symptoms in Patients with Obesity

Wissam Ghusn, MD, Lizeth Cifuentes, MD, Alejandro Campos, MD, Daniel Sacoto, MD, Alan De La Rosa, MD, Fauzi Feris, MD, Gerardo Calderon, MD, Daniel Gonzalez-Izundegui, MD, Jessica Stutzman, Maria Daniela Hurtado, MD, PhD, Michael Camilleri, MD, PhD, Andres Acosta, MD, PhD

PII: S2772-5723(22)00135-2
DOI: https://doi.org/10.1016/j.gastha.2022.07.019
Reference: GASTHA 166

To appear in: Gastro Hep Advances

Received Date: 5 July 2022
Revised Date: 20 July 2022
Accepted Date: 25 July 2022


This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier, Inc on behalf of the AGA Institute
Title: Association between Food Intake and Gastrointestinal Symptoms in Patients with Obesity

Short Title: Food Intake and Gastrointestinal Symptoms

Wissam Ghusn MD1, Lizeth Cifuentes MD1, Alejandro Campos MD1, Daniel Sacoto MD1, Alan De La Rosa MD1, Fauzi Feris MD1, Gerardo Calderon MD1, Daniel Gonzalez-Izundegui MD1, Jessica Stutzman1, Maria Daniela Hurtado MD, PhD1, Michael Camilleri MD, PhD2, Andres Acosta MD, PhD1

From

1 Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN

2 Clinical Enteric Neuroscience Translational and Epidemiology Research (C.E.N.T.E.R.) Mayo Clinic, Rochester, MN 55905

Grant Support: Dr. Acosta is supported by NIH (NIDDK K23-DK114460). Dr. Camilleri is supported by NIH (NIDDKRO1 DK67071).

Abbreviations: aBDQ: Abridged Bowel Disease Questionnaire, BMI: Body-Mass Index, CI: Confidence Intervals, CTF: Calories to Fullness, GE: Gastric Emptying, GI: Gastrointestinal, HADS: Hospital Anxiety and Depression Scale, IBS: irritable bowel syndrome, OR: Odds Ratios, VAS: Visual Analog Scale.

Corresponding Author: Andres Acosta, M.D., Ph.D.
Mayo Clinic, Charlton 8-142, 200 First St. S.W, Rochester, MN 55902
E-mail: acosta.andres@mayo.edu
Telephone number: 507-266-6931

Financial Disclosures: Dr. Acosta is a stockholder in Gila Therapeutics, Phenomix Sciences; he served as a consultant for Rhythm Pharmaceuticals, General Mills, and Amgen Pharmaceuticals. Dr. Camilleri is a stockholder in Phenomix Sciences and a consultant to Kallyope (with compensation to Mayo Clinic). There are no other disclosures.

Writing Assistance: None

Conflict of interest statement (for all authors): The authors declare no conflict of interest.

Data Transparency Statement: Deidentified individual participant data can be shared upon request

- Data on participants’ tests and questionnaire results; Bowel Disease Questionnaire
• Data can be sent to journal if needed
• No limited timeframe

Authors Contribution: Wissam Ghusn: Writing- Original draft preparation, Writing- Reviewing and Editing Software, Methodology; Lizeth Cifuentes, Alejandro Campos, Daniel Sacoto, Alan De La Rosa, and Fauzi Feris: Writing- Reviewing and Editing; Gerardo Calderon, Daniel Gonzalez-Izundegui, and Jessica Stutzman: Investigación and Resources; Maria Daniela Hurtado and Michael Camilleri: Supervision; Andres Acosta: Funding acquisition and Supervision

Ethical Statement: The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.

Abstract:

Background and Aims: Hunger, satiation, postprandial satiety, and hedonic eating constitute key food intake parameters. We aim to study whether these symptoms are associated with gastrointestinal symptoms (GIS) in patients with obesity.

Methods: This is a cross-sectional study of patients with obesity. Patients completed the following validated biomarkers and questionnaires: Hunger was measured via visual analog scale (100mm) following a standard meal, satiation via ad-libitum meal (calories to fullness;kcal), postprandial satiety via gastric emptying scintigraphy (T1/2;mins) and hedonic eating via the Hospital Anxiety and Depression Scale questionnaire. Participants completed the abridged Bowel-Disease-Questionnaire to evaluate their GIS. We calculated the odds ratios adjusted for sex, weight, and age between food intake parameters <25th or >75th percentile observed in a prior cohort of 450-participants with obesity and GIS.

Results: A total of 274 participants (41±10 [SD] years, 75% females, body-mass index 39±8kg/m²) were included in the analysis. Increased hunger was associated with a lower prevalence of lumpy stools (OR=0.18, p=0.02). Satiation was associated with abdominal pain/discomfort [relieved by defecation (OR=2.4, p=0.02) or associated with change in stool consistency (OR=2.92, p<0.01)], loose/watery stools (OR=2.09, p=0.02) and bloating (OR=2.49, p<0.01). Abnormal postprandial satiety was associated with bloating (OR=2.26, p<0.01) and loose/watery stools (OR=1.84, p=0.04). Hedonic eating was associated with abdominal pain/discomfort with stool frequency change (OR=2.4, p=0.02), >3 bowel movements/day (OR=1.93, p=0.048), bloating (OR=2.49, p=0.01), abdominal pain after meals >1/month (OR=4.24, p<0.01), and nausea >1/week (OR=4.51, p<0.01).

Conclusion: Alterations in hunger, satiation, postprandial satiety, and hedonic eating are associated with GIS in patients with obesity.
Keywords: Obesity; Hunger; Satiation; Postprandial Satiety, Gastric Emptying; Hedonic Eating
Introduction:

Obesity is a chronic multifactorial disease that results from increased energy intake and/or decreased energy expenditure. Energy balance is governed by food intake and energy expenditure. An imbalance between these two key factors can lead to weight gain. Food intake is regulated by homeostatic and hedonic factors; homeostatic factors can be further divided into three stages: hunger, satiation, and postprandial satiety. Hunger is an internal motivational state elicited by a lack of nutrients in the body, which drives eating and food-seeking behavior. Satiation is the process that brings an eating episode to an end, whereas postprandial satiety is the constellation of sensations that inhibits eating in the postprandial period and it is reflected objectively by gastric emptying (GE) time. In addition, hedonic eating is the desire to eat solely to elicit pleasurable feelings regardless of the individual’s nutritional status. Alterations in hunger, satiation, postprandial satiety and hedonic eating contribute to food intake symptoms. These symptoms led to the development of a phenotype-guided method which differentiates the causes of obesity based on the pathogenesis: satiation, postprandial satiety, hedonic eating, and resting energy expenditure. Importantly, these alterations have been only studied in patients with obesity or overweight. Such classification contributes to a better understanding and treatment of obesity.

Obesity affects almost every system in the body, raising the risk of a variety of illnesses. It can either be the primary cause, as seen in nonalcoholic fatty liver disease, or a substantial risk factor for numerous gastrointestinal (GI) and hepatic diseases such as reflux esophagitis caused by gastroesophageal reflux disease. Low-grade chronic inflammation, fluctuations in GI hormones, and adipose tissue redistribution in the abdominal cavity contribute to GI morbidity in obesity. Moreover, several studies show that food intake results in a significant colonic response change (e.g., fat composition). Obesity was also shown to be associated with chronic symptoms including dyspepsia, upper abdominal pain, diarrhea, heartburn, vomiting and retching. Furthermore, weight loss can play a possible role in improvement of common GI symptoms in patients with obesity, such as gastroesophageal reflux disease, abdominal distention, diarrhea and constipation.

Previously, satiation and satiety tests have been used to explore the prevalence of dyspepsia in the community. Postprandial fullness and early satiation are typical dyspeptic
symptoms that have been investigated using physiological GI tests such as GE of solids and liquids, gastric volumes, and liquid nutrient meal. However, little is known about the association between altered hunger, satiation, postprandial satiety, and hedonic eating with functional GI symptoms in patients with obesity. Although several studies measure the correlation between obesity and functional GI symptoms, none explain their association with food intake symptoms. Moreover, these studies are limited by inconsistent conclusions, selection bias, young-age participants, small sample size, and using diverse tools to measure same objective parameters (i.e., GE). In addition, none of the studies in the literature simultaneously examined food intake symptoms and their relationship with common GI symptoms in obesity. We hypothesized that food intake symptoms (e.g., altered hunger, satiation, postprandial satiety, and hedonic eating) are associated with diverse functional GI symptoms in obesity.

Methods:

Study design and participants

We performed a cross-sectional study analyzing baseline characteristics of adult participants between 18 and 65 years old with obesity (Body-mass Index [BMI] > 30 kg/m²) with no evidence of any chronic gastrointestinal diseases, use of medications that may alter gastrointestinal motility, appetite or absorption, active psychiatric symptoms, eating disorders (e.g., bulimia, binge eating disorder), or alcohol use disorder. This study was approved by the institutional human research review committee at Mayo Clinic. The participants were recruited from the community using standard advertisement and here we report the baseline characteristic of participants enrolled in the ClinicalTrials.gov NCT03374956 trial. In this study, all the physiological studies (i.e., GE and ad libitum meal) and questionnaires were completed to assess baseline characteristics of our patients prior to starting the clinical trial. All authors had access to the study data and reviewed and approved the final manuscript.

Measurements:

All tests were performed at the Mayo Clinic Clinical Research and Trial Unit after an 8-hour fasting period (Figure 1 and 2):

A. Hunger was evaluated using 100mm visual analog scale (VAS) after 240 mins of a 320-kcal standard breakfast meal.
B. Satiation was assessed by measuring calories to fullness (CTF) during an *ad libitum* meal.\(^{33}\)

C. Postprandial satiety was studied via measuring the gastric emptying (GE T\(_{1/2}\)) by scintigraphy for a total of 240 mins after radiolabeled solid (320-kcal, 30% fat) standard breakfast. Postprandial satiety has been previously associated with rapid GE by Gonzalez-Izundegui et al.\(^6\)

D. Hedonic eating was evaluated using the Hospital Anxiety and Depression Scale (HADS) questionnaire.\(^{33}\) A correlation between HADS anxiety score and the three-factor eating questionnaire (emotional eating factor; \(r=0.36\)) has been recently established. In addition, higher HADS anxiety scores were associated with emotional and uncontrolled eating (\(p<0.001\) for both), and lower levels of cognitive restraint (\(p=0.04\))\(^{34}\).

Participants completed the abridged Bowel Disease Questionnaire (aBDQ), a 16-item form that has been used to evaluate various functional GI symptoms (supplementary material)\(^{35}\).

Statistical analysis:

Using standard quantile regression approach to identify normal range\(^{36}\) and based on the fact that these variables are different in obesity when compared to healthy controls\(^{37}\), the abnormal traits in the key components of food intake were determined based on quartiles – 25\(^{th}\) or 75\(^{th}\) percentile as observed from our previous study\(^{33}\). Thus, the cutoffs were: increased hunger was defined as VAS-hunger: > 80 mm for females and > 87 mm for males; abnormal satiation was defined as *ad libitum* meal test > 970 Kcal for females and > 1359 Kcal for males; accelerated GE, which is a biomarker of abnormal postprandial satiety, was defined as <25\(^{th}\) percentile of GE T\(_{1/2}\): < 106 mins for females and < 87 mins for males; and hedonic eating was defined with a score >7 for HADS-Anxiety for both sexes (Table 1). We used a multivariate logistic regression model to calculate the odds ratios (OR) and 95% confidence intervals (CIs) associating hunger, satiation, postprandial satiety, and hedonic eating with the aBDQ results.
while adjusting for sex, weight, and age. Statistical significance was set at 2-sided p< 0.05. We used JMP®, Version 14.3.0 (SAS Institute Inc., Cary, NC, 1989-2019) to perform the statistical analysis. Data are summarized as mean (standard deviation).

**Results:**

Participants Demographics:

A total of 274 participants with obesity were recruited for this study. Our participants were predominantly females (75%), mean age 40.7 (10.3) years and BMI 39.2 (7.5) kg/m². The distribution of our participants among the hunger, satiation, postprandial satiety, and hedonic eating groups is shown in Table 2.

Association between food intake and GI symptoms

**Increased hunger** was associated with a lower prevalence of lumpy stools (OR 0.18, 95% CI 0.04-0.76; p= 0.02) (Figure 2A).

**Abnormal satiation** was associated with a higher frequency for ≥3 months of continuous or recurrent symptoms of abdominal pain or discomfort that is relieved by defecation (OR 2.4, 95% CI 1.15-5.01; p= 0.02), or associated with change in stool consistency (OR 2.92, 95% CI 1.34-6.34 p< 0.01), bloating (OR 2.49, 95% CI 1.33-4.66; p< 0.01), bloating after meals (OR 2.09, 95% CI 1.14-3.83; p= 0.02), and loose/watery stools (OR 2.09, 95% CI 1.14-3.84; p= 0.02) (Figure 2B).

**Abnormal postprandial satiety** was associated with a higher prevalence of bloating (OR 2.26, 95% CI 1.23-4.2; p< 0.01), bloating after meals (OR 1.83, 95% CI 1.02-3.29; p= 0.04), and loose/watery stools (OR 1.84, 95%CI 1.02-3.34; p= 0.04) (Figure 2C).
**Hedonic eating** was associated with a higher frequency for ≥3 months of continuous or recurrent symptoms of abdominal pain or discomfort associated with a change in stool frequency (OR 2.4, 95% CI 1.15-5.01; p= 0.02), > 3 bowel movements per day (OR 1.93 95% CI 1.005-3.692; p= 0.048), bloating (OR 2.49 95% CI 1.24-5; p= 0.01), upper abdominal pain after meals more than once a month (OR 4.24 95% CI 1.82-9.85; p< 0.01), bloating after meals (OR 2.1 95%CI 1.1-4.04; p= 0.03), and nausea regularly more than once a week (OR 4.51 95% CI 1.79-11.37; p< 0.01) (Figure 2D).

**Discussion:**

Our present study shows an association between symptoms associated with food intake and chronic functional GI symptoms in patients with obesity. These GI symptoms which are prevalent in obesity,\textsuperscript{26} seem to be linked to specific alterations in parameters of food intake. In fact, these symptoms associated with food intake are found to be coexisting with a wide range of upper (bloating, abdominal pain, nausea) and lower (diarrhea) GI symptoms.

Functional GI symptoms and obesity are highly prevalent in adults.\textsuperscript{25,26} Several studies show a high prevalence of various symptoms (i.e. bloating and diarrhea) in patients with obesity.\textsuperscript{38} Here, we showed the association of each component of food intake with GI symptoms. These components were labeled as increased or decreased based on the data in an independent cohort of 450 adults with obesity, from which we proposed a pathophysiological and behavioral phenotype-based classification of obesity.\textsuperscript{39} The correlation with GI symptoms is of potential clinical importance. First, it might provide the rationale to propose treatments to address both the obesity phenotype as well as postprandial symptoms. For example, it would be advantageous to treat abnormal postprandial satiety (associated with accelerated GE) and watery diarrhea with an agent that delays gastrointestinal motility and GE such as a GLP-1 agonist.\textsuperscript{40,41}
A second rationale is that both abnormal food intake and GI symptoms are highly prevalent and may co-exist in the same person; thus, abnormal satiation is present in 32% of patients with obesity and bloating is reported in 31% of the general population.42

**Hunger and lumpy stools:** The association between increased hunger and lower prevalence of lumpy stools may be explained by diverse mechanisms. Hunger is one of the driving factors of food intake and perhaps craving for high fat intake, which can stimulate a colonic motor response, increased colonic phasic contractile activity and therefore, avoidance of constipation, or the associated lumpy stools (type 1 or 2 on the Bristol Stool Form Scale). Increased hunger may also reflect a higher level of ghrelin in the body. Ghrelin and its analogs (e.g. relamorelin) regulate GI motility by accelerating gastric and intestinal motility, and may play a potential role in treating constipation by stimulating gastrointestinal motility and significantly changing stool consistency as previously shown in a placebo-controlled trial of relamorelin.52

**Satiation and GI symptoms:** Abnormal satiation in this study is reflected in increased intake of calories at an ad libitum meal; the sensation of bloating in patients with abnormal satiation is poorly understood but it is conceivable that it reflects increased visceral afferent activation as occurs with dyspeptic symptoms, and may result in changes in eating habits.

Continuous or recurrent abdominal pain or discomfort for at least 6 months associated with a change in stool frequency, change in stool form, and related to defecation are the three Rome IV criteria for irritable bowel syndrome (IBS) classification. Any patient with ≥2 of these bowel function symptoms is sufficient for IBS diagnosis. Our study showed that participants with abnormally higher satiation level (that is increased kcal intake) are more likely to have abdominal pain associated with change in stool frequency and/or relieved by defecation.
However, other studies show that patients with IBS have a similar satiation level compared to healthy individuals.\textsuperscript{56} Similarly, ingesting certain types of food in high quantities can promote osmotic diarrhea which can partially explain the high prevalence of diarrhea in patients with obesity. Patients with obesity and abnormal satiation are more likely to ingest a greater quantity of food \textsuperscript{29} containing poorly absorbed sugars (i.e., fructose corn syrup) that can contribute to diarrhea.

**Postprandial Satiety and GI symptoms:** Patients with rapid GE may present with dyspepsia symptoms (e.g., bloating),\textsuperscript{14,57} possibly as a result of rapid transit of hyperosmolar food into the duodenum, as occurs in dumping syndrome,\textsuperscript{58} which is associated with bloating especially after meals.\textsuperscript{59}

In a study on patients with chronic diarrhea, Charles et al, showed a higher prevalence of rapid GE which may be a possible mechanism of diarrhea in patients with functional bowel disorders.\textsuperscript{60} Similarly, in our study, patients with accelerated GE were more likely to report watery, loose stools.

**Hedonic eating and GI symptoms:** Anxiety has been previously linked to increased food intake is a subset of patient with obesity,\textsuperscript{39} and it has been associated with bloating\textsuperscript{61}, functional abdominal pain\textsuperscript{62}, and nausea\textsuperscript{63}. In addition, previous studies show an increased susceptibility of hedonic eating in female patients which account for 75\% of our cohort.\textsuperscript{64}

Strength and limitations:
The strengths of our study include the adequate sample size of participants who completed simultaneously during the same day the required tests and questionnaires, exclusion of patients with any GI disease and eating disorder, and the nature of the cross-sectional study which limits the attrition bias.
This study also has several potential limitations. Considering the nature of our study, no casual inference can be made for any of the results. In fact, we cannot study the temporal relation between the food intake and the chronic GI symptoms. For example, it cannot be concluded whether higher levels of anxiety were due to GI symptoms in obesity or vice versa. In addition, our participants were required to fill in questionnaires which makes the study more susceptible to recall bias. This study also included mostly white Americans and female patients which limits the generalizability of our results to other populations.

Conclusion:

In patients with obesity, homeostatic (hunger, satiation, and postprandial satiety) and hedonic components of food intake are associated with various chronic GI symptoms. These symptoms are known to be observed with a significantly higher prevalence in patients with obesity. Our study further shows an association between food intake and functional GI symptoms. This linkage requires more study to better understand, treat and prevent the occurrence of such GI symptoms in obesity.
References:
11. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97.
43. Davis J. Hunger, ghrelin and the gut. Brain Res 2018;1693:154-158.

Tables and Figures:

Table 1:
Cohort distribution of participants adjusted by sex upon the food intake tests.

<table>
<thead>
<tr>
<th>Food Intake Tests</th>
<th>Abnormal Value</th>
<th>Cut-off</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Hunger (VAS, mm)</td>
<td>&gt;80</td>
<td>&gt;87</td>
</tr>
<tr>
<td>Satiation (Ad Libitum meal, Kcal)</td>
<td>&gt;970</td>
<td>&gt;1359</td>
</tr>
<tr>
<td>Postprandial Satiety (Gastric Emptying T½, min)</td>
<td>&lt;106</td>
<td>&lt;87</td>
</tr>
<tr>
<td>Hedonic Eating Behavior (HADS, score)</td>
<td>&gt;7</td>
<td>&gt;7</td>
</tr>
</tbody>
</table>

Abbreviations: HADS, hospital anxiety and depression scale; VAS, visual analogue scale.

Table 2:
Demographic distribution of the hunger, satiation, postprandial satiety, and hedonic eating groups of participants.

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Hunger</th>
<th>Satiation</th>
<th>Postprandial Satiety</th>
<th>Hedonic Eating</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal</td>
<td>Abnormal</td>
<td>P-value</td>
<td>Normal</td>
</tr>
<tr>
<td>Participants, n</td>
<td>215</td>
<td>51</td>
<td>0.76</td>
<td>205</td>
</tr>
<tr>
<td>Age, y</td>
<td>41±10</td>
<td>40±10</td>
<td>0.02</td>
<td>41±10</td>
</tr>
<tr>
<td>Sex, Female (%)</td>
<td>155 (72)</td>
<td>45 (88)</td>
<td></td>
<td>154 (75)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>114±26</td>
<td>108±21</td>
<td>0.09</td>
<td>110±25</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>40±7.6</td>
<td>38.5±7.3</td>
<td>0.70</td>
<td>41±8.3</td>
</tr>
</tbody>
</table>

Figure 1: The flowchart of the testing day.
Figure 2: The food intake parameters and their assessment methods.
**Figure 3:** The odds ratio of gastrointestinal symptoms based in the bowel disease questionnaire in patients with obesity and abnormal hunger (A), satiation (B), postprandial satiety (C), or hedonic eating (D).
### Table 1: Cohort distribution of participants adjusted by sex upon the food intake tests.

<table>
<thead>
<tr>
<th>Food Intake Tests</th>
<th>Abnormal Value</th>
<th>Cut-off</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Hunger (VAS, mm)</td>
<td>&gt;80</td>
<td>&gt;87</td>
</tr>
<tr>
<td>Satiation (Ad Libitum meal, Kcal)</td>
<td>&gt;970</td>
<td>&gt;1359</td>
</tr>
<tr>
<td>Postprandial Satiety (Gastric Emptying T½, min)</td>
<td>&lt;106</td>
<td>&lt;87</td>
</tr>
<tr>
<td>Hedonic Eating Behavior (HADS, score)</td>
<td>&gt;7</td>
<td>&gt;7</td>
</tr>
</tbody>
</table>

Abbreviations: HADS, hospital anxiety and depression scale; VAS, visual analogue scale.
<table>
<thead>
<tr>
<th>Demographics</th>
<th>Hunger</th>
<th>Satiation</th>
<th>Postprandial Satiety</th>
<th>Hedonic Eating</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal</td>
<td>Abnormal</td>
<td>P-value</td>
<td>Normal</td>
</tr>
<tr>
<td>Participants, n</td>
<td>215</td>
<td>51</td>
<td>205</td>
<td>68</td>
</tr>
<tr>
<td>Age, y</td>
<td>41±10</td>
<td>40±10</td>
<td>0.76</td>
<td>41±10</td>
</tr>
<tr>
<td>Sex, Female (%)</td>
<td>155 (72)</td>
<td>45 (88)</td>
<td>0.02</td>
<td>154 (75)</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>114±26</td>
<td>108±21</td>
<td>0.09</td>
<td>110±25</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>40±7.6</td>
<td>38.5±7.3</td>
<td>0.70</td>
<td>41±8.3</td>
</tr>
</tbody>
</table>

Table 2:
Demographic distribution of the hunger, satiation, postprandial satiety, and hedonic eating groups of participants.
Visual Analog Scale → Hunger: Desire to eat

Ad Libitum meal → Satiation: Knowing when the meal is over

Gastric Emptying → Postprandial Satiety: Eating inhibition in the postprandial period

Hospital Anxiety and Depression Scale → Hedonic Eating: Eating in response to emotions
A. Abdominal pain associated with stool frequency
   Lumpy stools
   > 3 bowel movements
   Nausea
   Upper abdominal pain
   Abdominal bloating
   Abdominal pain relieved by defecation
   Abdominal pain associated with stool consistency
   Watery stools
   Bloating

B. Abdominal pain associated with stool frequency
   Lumpy stools
   > 3 bowel movements
   Nausea
   Upper abdominal pain
   Abdominal bloating
   Abdominal pain relieved by defecation
   Abdominal pain associated with stool consistency
   Watery stools
   Bloating

C. Abdominal pain associated with stool frequency
   Lumpy stools
   > 3 bowel movements
   Nausea
   Upper abdominal pain
   Abdominal bloating
   Abdominal pain relieved by defecation
   Abdominal pain associated with stool consistency
   Watery stools
   Bloating

D. Abdominal pain associated with stool frequency
   Lumpy stools
   > 3 bowel movements
   Nausea
   Upper abdominal pain
   Abdominal bloating
   Abdominal pain relieved by defecation
   Abdominal pain associated with stool consistency
   Watery stools
   Bloating